baseline hematologic abnormalities (ie, neutropenia) can be exacerbated by interferon (IFN) alfa and ribavirin-containing HCV therapy. 10 Other reasons for excluding these patients is the potential for HCV to affect the toxicity and/or efficacy of the
Search Results
Effect of Hepatitis C Virus Infection in Patients With Cancer: Addressing a Neglected Population
Harrys A. Torres, Parag Mahale, Boris Blechacz, Ethan Miller, Ahmed Kaseb, H. Franklin Herlong, Nathan Fowler, Ying Jiang, Issam I. Raad, and Dimitrios P. Kontoyiannis
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
Daniel A. Pollyea, Jessica K. Altman, Rita Assi, Dale Bixby, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Brian A. Jonas, Ashwin Kishtagari, Jeffrey Lancet, Lori Maness, James Mangan, Gabriel Mannis, Guido Marcucci, Alice Mims, Kelsey Moriarty, Moaath Mustafa Ali, Jadee Neff, Reza Nejati, Rebecca Olin, Mary-Elizabeth Percival, Alexander Perl, Amanda Przespolewski, Dinesh Rao, Farhad Ravandi, Rory Shallis, Paul J. Shami, Eytan Stein, Richard M. Stone, Kendra Sweet, Swapna Thota, Geoffrey Uy, Pankit Vachhani, Carly J. Cassara, Deborah A. Freedman-Cass, and Katie Stehman
neutropenia, myelosuppression was generally modest and reversible, potentially reflecting the minimal expression of IL3R on normal myeloid progenitors. Many patients experienced transaminitis without hyperbilirubinemia, with onset typically 5 to 10 days
Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer
Dong Ding, Huabin Hu, Shuosha Li, Youwen Zhu, Yin Shi, Mengting Liao, Jin Liu, Xu Tian, Aiting Liu, and Jin Huang
durvalumab. Other considerable influential parameters were risk of neutropenia in chemotherapy group, risk of neutropenia in durvalumab group, and utility of PD. Figure 1. Tornado diagram for one-way sensitivity analysis. Abbreviations: ICER
Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer
Zachary Veitch, Omar F. Khan, Derek Tilley, Patricia A. Tang, Domen Ribnikar, Douglas A. Stewart, Xanthoula Kostaras, Karen King, and Sasha Lupichuk
practices, Shayne et al 30 identified significant predictors of chemotherapy dose reduction, including BSA >2 m 2 , age ≥65 years, febrile neutropenia, and comorbidities (particularly renal disease). In other retrospective studies, obesity has been
Changes in Prescribing Patterns in Stage III Colon Cancer
Fang-Shu Ou, Daniel J. Walden, Joseph J. Larson, Sandra Kang, Cassia R. Griswold, Benjamin E. Ueberroth, Bhamini Patel, Amber Draper, Puneet Raman, Olatunji B. Alese, Mohamad B. Sonbol, Tanios S. Bekaii-Saab, Christina S. Wu, and Daniel H. Ahn
(trAEs), including neutropenia, thrombocytopenia, and permanent peripheral neuropathy, that may limit the clinical benefits of FOLFOX chemotherapy. 5 Given the need to balance survival outcomes with toxicity, the IDEA collaboration aimed to evaluate the
Resurrection of PARP Inhibitors in Breast Cancer
Tomas G. Lyons and Mark E. Robson
anemia (39.2% vs 4.8%) and thrombocytopenia (14.7% vs 1.6%); however, grade 3 or 4 neutropenia was less frequent with talazoparib (20.9% vs 34.9%). Veliparib Veliparib has been evaluated as both a monotherapy and in combination with chemotherapy
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Steven M. Horwitz, Stephen Ansell, Weiyun Z. Ai, Jeffrey Barnes, Stefan K. Barta, Jonathan Brammer, Mark W. Clemens, Ahmet Dogan, Francine Foss, Paola Ghione, Aaron M. Goodman, Joan Guitart, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric Jacobsen, Deepa Jagadeesh, Allison Jones, Avyakta Kallam, Youn H. Kim, Kiran Kumar, Neha Mehta-Shah, Elise A. Olsen, Saurabh A. Rajguru, Sima Rozati, Jonathan Said, Aaron Shaver, Lauren Shea, Michi M. Shinohara, Lubomir Sokol, Carlos Torres-Cabala, Ryan Wilcox, Peggy Wu, Jasmine Zain, Mary Dwyer, and Hema Sundar
histologic subtypes due to small subgroup sizes. Neutropenia (35%), anemia (13%), diarrhea (6%), peripheral neuropathy (4%), and nausea (2%) were the most common grade ≥3 adverse events with brentuximab vedotin + CHP. Peripheral neuropathy associated with
Abstracts From the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™
vomiting; grade 3/4 AEs included thrombocytopenia, anemia, and neutropenia. Table 1 shows the ORRs and clinical benefit rates (CBRs) for evaluable patients in all arms. Conclusions: Oral qw Sd in combination with other anti-MM agents is generally well
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Shaji K. Kumar, Natalie S. Callander, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Matthew Faiman, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Michaela Liedtke, Thomas Martin, James Omel, Noopur Raje, Frederic J. Reu, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead, and Rashmi Kumar
%), hyperglycemia (23%), anemia (21%), thrombocytopenia (17%), and neutropenia (17%). Peripheral neuropathy was limited to grade 1/2 (23%). 84 The second phase II trial also evaluated the same regimen (carfilzomib in combination with lenalidomide and dexamethasone
Diffuse Large B-Cell Lymphoma Version 1.2016
Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Matthew Lunning, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, and Hema Sundar
were 75·4% and 74·8%, respectively ( P =5907). Toxicity was similar, except for a lower rate of grade 3 or 4 neutropenia in the R-CHOP-14 arm (31% vs 60%), reflecting the fact that all patients in the R-CHOP-14 arm received primary growth factor
